Gut Microbiota–Nanotechnology Interface: A New Frontier in Managing Obesity and Diabetes
Winniefred Nankya
Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug
ABSTRACT
The gut microbiota plays a crucial role in maintaining metabolic homeostasis and influencing the development of obesity and type 2 diabetes (T2D). Dysbiosis, an imbalance in gut microbial composition, has been linked to insulin resistance, inflammation, and disrupted glucose metabolism. Recent advances in nanotechnology offer promising solutions to modulate the gut microbiota and its associated metabolic functions. Nanoparticles (NPs) can deliver therapeutic agents, regulate microbial composition, and enhance gut barrier function, all of which contribute to managing obesity and diabetes. This review explores the interface between gut microbiota and nanotechnology, highlighting the mechanisms through which nanoparticles influence microbial diversity, the therapeutic potential of nanomaterials in metabolic disease management, and the challenges and future directions for clinical application.
Keywords: gut microbiota, nanotechnology, obesity, diabetes, metabolic disease
CITE AS: Winniefred Nankya (2026). Gut Microbiota–Nanotechnology Interface: A New Frontier in Managing Obesity and Diabetes. IAA Journal of Biological Sciences 14(1):82-86.